Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease
- 14 March 2024
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (7) , 918-927
Abstract
Allogeneic stem cell transplantation (Allo-SCT) is the only rapidly available curative treatment modality in patients with severe sickle cell disease (SCD). The development of reduced-toxicity myeloablative conditioning (RT-MAC) regimen and the use of partially matched family donors with post-transplantation cyclophosphamide (PT-Cy) have widened the access to Allo-SCT. Antibodies against donor-specific HLA (DSA) increase the risk of engraftment failure in HLA mismatched Allo-SCT. We report the results of five patients with SCD, whereas three with DSA, who underwent an unmanipulated haploidentical stem cell transplantation (Haplo-SCT) after a busulfan-based RT-MAC regimen with PT-Cy. To reduce the risk of engraftment failure, a sequential two courses pharmacological pre-transplant immune suppression (PTIS) phase was added prior to the conditioning regimen. All patients engrafted successfully. The procedure was well tolerated. None of the patients developed acute GVHD, whereas one developed moderate chronic GVHD. After a median follow-up of 5 years (range, 2.2–9), all patients are free of pain with excellent quality of life. Our report shows that Haplo-SCT after a RT-MAC regimen is feasible and safe with stable long-term engraftment and excellent disease control. The risk of graft failure can be abrogated by adding a PTIS phase prior to initiating the conditioning regimen.Keywords
This publication has 43 references indexed in Scilit:
- Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European PatientsJAMA Oncology, 2019
- HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell DiseaseTransplantation and Cellular Therapy, 2018
- Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell diseaseAnnals of Hematology, 2017
- Health-Related Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell DiseaseTransplantation and Cellular Therapy, 2015
- Outcomes of Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation by Using a Standard Myeloablative versus a Novel Reduced-Toxicity Conditioning Regimen According to a New Risk StratificationTransplantation and Cellular Therapy, 2014
- Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell PhenotypeJAMA, 2014
- Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific AntibodiesTransplantation and Cellular Therapy, 2013
- Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)Transplantation and Cellular Therapy, 2012
- Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell DiseaseTransplantation and Cellular Therapy, 2011
- Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell diseaseAmerican Journal of Hematology, 2009